Enhanced Secretory Leukocyte Protease Inhibitor in Human Immunodeficiency Virus Type 1-Infected Patients

Secretory leukocyte protease inhibitor (SLPI) has been found to possess activity against the human immunodeficiency virus type 1 (HIV-1) in vitro at physiological concentrations. A study was undertaken to evaluate SLPI levels in human saliva and plasma among HIV-positive (HIV(+)) patients with vario...

Полное описание

Библиографические подробности

Опубликовано в::	Clin Diagn Lab Immunol
Главные авторы:	Baqui, A. A. M. A., Meiller, Timothy F., Falkler, William A.
Формат:	Artigo
Язык:	Inglês
Опубликовано:	American Society for Microbiology (ASM) 1999
Предметы:	Article
Online-ссылка:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC95780/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/10548568/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/cdli.6.6.808-811.1999
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!